Navigation Links
Reportlinker Adds Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies

http://www.reportlinker.com/p0284881/Triple-Analysis-Lymphoma-Cancer-Vaccines-and-Antibodies.html

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma

The lymphoma report part includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, T-cell lymphoma and Lymphoma (general)). This report part extensively analyses 124 identified targets of lymphoma drugs, organized into 109 drug target strategies, and assesses them in lymphoma.

This part is based on the following publication:

Lymphoma Drug Development Strategies at Work - Define Your Competition

Part II: Cancer Vaccines

The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.

This part is based on the following publication:

Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

Part III: Antibodies

The antibody report part comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. This report part extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target strategies, and assesses them in 69 different cancer indications.

This part is based on the following publication:

Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma

5.1 The Scope of this Report 22

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (124 Drug Targets) 26-250

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline? (109 Drug Target Strategies and 176 Drugs) 251-280

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound (6 Different Compound Strategies) 281-312

9 Selecting a Sub-Indication of Lymphoma for Drug Development 313-450

10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator (106 Investigators) 351-524

12 Drug Index 526

13 Company Index 531

Figures: Includes 17 Figures

Tables: Includes 164 Tables

Total Number of Pages: 535

Part II: Cancer Vaccines

5.1 The Scope of this Report 26

6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets) 30-194

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs) 195-308

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 309-338

9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications) 339-386

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators) 387-649

11 Disclaimer 650

12 Drug Index 651

13 Company Index 656

Figures: Includes 6 Figures

Tables: Includes 205 Tables

Total Number of Pages: 659

Part III: Antibodies

5.2 The Scope of this Report 30

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (225 Drug Targets) 36-319

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic Pipeline? (234 Drug Target Strategies and 441 Drugs) 320-383

8 Selecting Cancer Indications for Antibody Therapeutics (69 Different Cancer Indications) 384-499

9 Portfolio Planning: Competitive Benchmarking of Antibody Cancer Therapeutic Pipeline by Investigator (168 Investigators) 500-1268

11 Drug Index 1270

12 Company Index 1282

Figures: Includes 5 Figures

Tables: Includes 302 Tables

Total Number of Pages: 1289

To order this report:

Drug Discovery and Development Industry: Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds BioMEMS 2010
2. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
3. Reportlinker Adds Breast Cancer Drug Futures
4. Reportlinker Adds Industrial Biotechnology China News 1009
5. Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry
6. Reportlinker Adds Global Food Safety Testing Industry
7. Reportlinker Adds Photovoltaic Technology Roadmap
8. Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025
9. Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses
10. Reportlinker Adds US Forensic Technologies and Services Industry
11. Reportlinker Adds Global Synthetic Biology Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... new report "DNA Sequencing - Technologies, Markets and Companies" ... ... This report briefly reviews basics of human genome variations, development ... sequencers are described as well as companies developing them. Various ...
(Date:12/4/2016)... , Dec. 3, 2016  In five studies ... Hematology (ASH) Annual Meeting and Exposition in ... engineering methods to improve the delivery of life-saving treatments ... new methods are designed to carry therapies directly to ... most, which could provide a substantial advantage over traditional, ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma ... from the MMRF CoMMpass Study SM —the largest and ... precision medicine in multiple myeloma—will be presented at the ... Meeting & Exposition in San Diego ... to optimize treatment strategies, as well as identify pathways ...
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):